Thirteen years of culture-positive M. bovis-BCG infection in an IL-12Rbeta1 deficient patient: treatment and outcome.
Patients with mutations in the IFNgamma/IL-12 pathway show an exquisite susceptibility to mycobacterial diseases. An IL-12Rbeta1 deficient patient with impaired intestinal absorption suffered from a 13 year culture-positive Mycobacterium bovis-BCG infection with acquired multidrug resistance. A combined parenteral and enteral anti-mycobacterial treatment, including recombinant IFNgamma, helped to clear his infection.
Rosenzweig
S D
SD
Servicio de Inmunología, Hospital Nacional de Pediatría J.P. Garrahan, Buenos Aires, Argentina. srosenzweig@garrahan.gov.ar
Yancoski
J
J
Bernasconi
A
A
Krasovec
S
S
Marciano
B E
BE
Casimir
L
L
Berberian
G
G
Símboli
N
N
Rousseau
M
M
Calle
G
G
D000293:Adolescent; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D009163:Mycobacterium bovis / Q000302:isolation & purification*; D053707:Receptors, Interleukin-12 / Q000172:deficiency* / Q000235:genetics; D014376:Tuberculosis / Q000188:drug therapy* / Q000235:genetics* / Q000382:microbiology
D000995:Antitubercular Agents; C508438:IL12RB1 protein, human; D053707:Receptors, Interleukin-12